AptarGroup, Inc.ATR
NYSE•Healthcare•Medical Instruments & Supplies
AptarGroup, Inc. designs and manufactures drug delivery, consumer product dispensing, and active material science solutions and services for the pharmaceutical, fragrance, facial skincare, color cosmetics, personal care, home care, and food and beverage markets. The company operates through three segments: Pharma, Beauty, and Closures. It provides dispensing pumps used to dispense sprays, liquids, or lotions from non-pressurized containers; fine-mist pumps for pharmaceutical and fragrance applications; and lotion pumps for viscous formulations, as well as closures, such as dispensing and non-dispensing solutions that enable product delivery without removal of the cap and used across various consumer end markets. The company also offers aerosol valves used in pressurized containers and continuous spray and metered-dose valves for pharmaceutical, personal care, and household applications; elastomeric primary packaging components; active material science solutions; and digital health solutions. The company primarily sells its products and services in Asia, Europe, Latin America, and North America. AptarGroup, Inc. was incorporated in 1992 and is headquartered in Crystal Lake, Illinois.
AptarGroup, Inc. (ATR) reported trailing twelve months revenue of $3.87B as of March 2026, a 8.9% increase year-over-year. Quarterly revenue reached $982.87M, reflecting continued top-line momentum.
AptarGroup, Inc. generated $386.60M in TTM net income, with quarterly EBITDA of $183.22M. The operating margin contracted from 12.8% to 10.9%, suggesting rising cost pressures or pricing headwinds.
The spread between operating margin (10.9%) and net margin (7.4%) indicates tight cost control with minimal non-operating drag. Net margin has narrowed from 8.9% a year ago, reflecting increased costs or interest expense.
ATR trades at a P/E of 19.6x (in line with broad market averages) and a P/S of 2.0x. The price-to-book ratio of 2.9x reflects a moderate premium to book value.
The company generated $53.30M in free cash flow over the trailing twelve months, a 105.9% increase year-over-year, indicating cash generation ability. The balance sheet shows $5.10B in total assets with $1.14B in long-term debt against $2.63B in stockholders equity for a debt-to-equity ratio of 0.4, a conservative capital structure. Data based on the most recent quarterly reports.
Competitive analysis based on 21 quarters of fundamental data
Operating margins are positive at ~13.4% on average, but show some variability — pricing power may be sensitive to market conditions.
ROE is positive at ~14.4% on average, adequate but below the threshold typically associated with wide moats.
8 of the last 8 quarters generated positive FCF. The company generally funds itself but has occasional cash consumption quarters.
TTM revenue has grown consistently (6 of 7 quarters up), with ~8.9% growth over the period. Strong demand durability.
Data-driven red flags and warnings across 21 quarters
Operating margins declined 8.6% — watch for continued compression, which may signal competitive or cost pressure.
FCF covers net income by 0.9x on average — earnings are well-supported by cash generation.
Debt-to-equity has risen 96.6% recently — increasing financial risk even if the current ratio is manageable.
Revenue is stable or growing over recent quarters — demand appears durable.
Free cash flow is consistently positive — the business self-funds without external capital reliance.
Shares decreased 3.4% — net buybacks are reducing shares outstanding and boosting per-share value.
Quarterly standardized metrics.
Stock price and market valuation
Revenue and earnings growth across quarters
Assets, cash, debt, and leverage
Price multiples and return ratios
Operating efficiency and return metrics
Free cash flow, earnings quality, and capital allocation